Cargando…

Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients

BACKGROUND: Autoimmune hepatitis (AIH) is an immune-mediated liver disease of unknown etiology. Increasing incidence of AIH in Asian patients has been reported. However, the phenotypic difference of Asian patients in Europe and Asia has still not been explored. AIM: To evaluate the clinical presenta...

Descripción completa

Detalles Bibliográficos
Autores principales: Than, Nwe Ni, Ching, Doreen Koay Siew, Hodson, James, McDowell, Patrick, Mann, Jake, Gupta, Ravi, Salazar, Ennaliza, Ngu, Jing Hieng, Oo, Ye Htun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939157/
https://www.ncbi.nlm.nih.gov/pubmed/27101826
http://dx.doi.org/10.1007/s12072-016-9727-4
_version_ 1782441962125656064
author Than, Nwe Ni
Ching, Doreen Koay Siew
Hodson, James
McDowell, Patrick
Mann, Jake
Gupta, Ravi
Salazar, Ennaliza
Ngu, Jing Hieng
Oo, Ye Htun
author_facet Than, Nwe Ni
Ching, Doreen Koay Siew
Hodson, James
McDowell, Patrick
Mann, Jake
Gupta, Ravi
Salazar, Ennaliza
Ngu, Jing Hieng
Oo, Ye Htun
author_sort Than, Nwe Ni
collection PubMed
description BACKGROUND: Autoimmune hepatitis (AIH) is an immune-mediated liver disease of unknown etiology. Increasing incidence of AIH in Asian patients has been reported. However, the phenotypic difference of Asian patients in Europe and Asia has still not been explored. AIM: To evaluate the clinical presentation, biochemical and immunological profiles, treatment response and survival outcome of type 1 AIH from two tertiary liver transplant centres (United Kingdom and Singapore). METHOD: Patients who fulfilled the simplified diagnostic scoring criteria of AIH were included in the study. Patients with overlap syndrome were excluded. RESULTS: Totals of 40 Asian patients and 159 Caucasian patients from the University Hospital of Birmingham National Health Service Foundation Trust, UK, were compared with 57 Asian patients from Singapore General Hospital, Singapore. Asian patients from Singapore present significantly much later (median 55 vs. 32 years, p < 0.001), had higher MELD (p < 0.001) with lower albumin (p < 0.001) and higher bilirubin (p < 0.001) and lower ASMA positivity (p < 0.001) at diagnosis compared to UK Asian. Jaundice at presentation was much higher in Singapore Asian patients compared to UK Asian (53 vs. 30 %) but cirrhosis at diagnosis was more common in UK patients. Associated autoimmune conditions were less commonly seen in Singapore Asians. Comparing between UK cohorts, Asian patients present at younger age and have higher IgG level compared to Caucasian. Overall, 5-year transplant-free survival in all three cohorts was similar (p = 0.846). CONCLUSION: We demonstrate that AIH patients from Singapore present at older age with jaundice and have a low positivity of SMA. Despite these differences, transplant-free survival is similar in the two groups.
format Online
Article
Text
id pubmed-4939157
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-49391572016-07-21 Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients Than, Nwe Ni Ching, Doreen Koay Siew Hodson, James McDowell, Patrick Mann, Jake Gupta, Ravi Salazar, Ennaliza Ngu, Jing Hieng Oo, Ye Htun Hepatol Int Original Article BACKGROUND: Autoimmune hepatitis (AIH) is an immune-mediated liver disease of unknown etiology. Increasing incidence of AIH in Asian patients has been reported. However, the phenotypic difference of Asian patients in Europe and Asia has still not been explored. AIM: To evaluate the clinical presentation, biochemical and immunological profiles, treatment response and survival outcome of type 1 AIH from two tertiary liver transplant centres (United Kingdom and Singapore). METHOD: Patients who fulfilled the simplified diagnostic scoring criteria of AIH were included in the study. Patients with overlap syndrome were excluded. RESULTS: Totals of 40 Asian patients and 159 Caucasian patients from the University Hospital of Birmingham National Health Service Foundation Trust, UK, were compared with 57 Asian patients from Singapore General Hospital, Singapore. Asian patients from Singapore present significantly much later (median 55 vs. 32 years, p < 0.001), had higher MELD (p < 0.001) with lower albumin (p < 0.001) and higher bilirubin (p < 0.001) and lower ASMA positivity (p < 0.001) at diagnosis compared to UK Asian. Jaundice at presentation was much higher in Singapore Asian patients compared to UK Asian (53 vs. 30 %) but cirrhosis at diagnosis was more common in UK patients. Associated autoimmune conditions were less commonly seen in Singapore Asians. Comparing between UK cohorts, Asian patients present at younger age and have higher IgG level compared to Caucasian. Overall, 5-year transplant-free survival in all three cohorts was similar (p = 0.846). CONCLUSION: We demonstrate that AIH patients from Singapore present at older age with jaundice and have a low positivity of SMA. Despite these differences, transplant-free survival is similar in the two groups. Springer India 2016-04-21 /pmc/articles/PMC4939157/ /pubmed/27101826 http://dx.doi.org/10.1007/s12072-016-9727-4 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Than, Nwe Ni
Ching, Doreen Koay Siew
Hodson, James
McDowell, Patrick
Mann, Jake
Gupta, Ravi
Salazar, Ennaliza
Ngu, Jing Hieng
Oo, Ye Htun
Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients
title Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients
title_full Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients
title_fullStr Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients
title_full_unstemmed Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients
title_short Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients
title_sort difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between united kingdom and singapore patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939157/
https://www.ncbi.nlm.nih.gov/pubmed/27101826
http://dx.doi.org/10.1007/s12072-016-9727-4
work_keys_str_mv AT thannweni differenceinclinicalpresentationimmunologyprofileandtreatmentresponseoftype1autoimmunehepatitisbetweenunitedkingdomandsingaporepatients
AT chingdoreenkoaysiew differenceinclinicalpresentationimmunologyprofileandtreatmentresponseoftype1autoimmunehepatitisbetweenunitedkingdomandsingaporepatients
AT hodsonjames differenceinclinicalpresentationimmunologyprofileandtreatmentresponseoftype1autoimmunehepatitisbetweenunitedkingdomandsingaporepatients
AT mcdowellpatrick differenceinclinicalpresentationimmunologyprofileandtreatmentresponseoftype1autoimmunehepatitisbetweenunitedkingdomandsingaporepatients
AT mannjake differenceinclinicalpresentationimmunologyprofileandtreatmentresponseoftype1autoimmunehepatitisbetweenunitedkingdomandsingaporepatients
AT guptaravi differenceinclinicalpresentationimmunologyprofileandtreatmentresponseoftype1autoimmunehepatitisbetweenunitedkingdomandsingaporepatients
AT salazarennaliza differenceinclinicalpresentationimmunologyprofileandtreatmentresponseoftype1autoimmunehepatitisbetweenunitedkingdomandsingaporepatients
AT ngujinghieng differenceinclinicalpresentationimmunologyprofileandtreatmentresponseoftype1autoimmunehepatitisbetweenunitedkingdomandsingaporepatients
AT ooyehtun differenceinclinicalpresentationimmunologyprofileandtreatmentresponseoftype1autoimmunehepatitisbetweenunitedkingdomandsingaporepatients